Companies Sellas Life Sciences Group
Sellas Life Sciences (SLS): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Sellas Life Sciences Group’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,752,638FY2023
- $1,189,773FY2024
- $1,877,810FY2025
CEO total pay was $1,877,810 in fiscal 2025, up from $1,189,773 in fiscal 2024.
FY2025: salary $676,000 · bonus $0 · stock awards $477,107 · option awards $327,695
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Angelos Stergiou | $676,000 | $0 | $477,107 | $327,695 | $390,390 | $0 | $6,618 | $1,877,810 |
| President and Chief Executive Officer | ||||||||
| Dragan Cicic | 451,234 | 0 | 185,071 | 143,990 | 193,128 | 0 | 18,372 | 991,795 |
| Senior Vice President, Chief Development Officer | ||||||||
| John Burns | 429,605 | 0 | 185,071 | 143,990 | 185,589 | 0 | 15,398 | 959,653 |
| Senior Vice President, Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Angelos Stergiou | $1,877,810 | $1,189,773 | $1,752,638 | ↑ +688,037 |
| Dragan Cicic | 991,795 | — | — | — |
| John Burns | 959,653 | 680,778 | 797,708 | ↑ +278,875 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The compensation of our named executive officers is designed to enable us to attract and retain talented and experienced executives capable of leading the Company successfully in a competitive environment. We believe that our compensation policies and decisions are focused on pay-for-performance principles, are strongly aligned with our stockholders' interests, and are effective in achieving the overall objectives of our compensation program.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford, a division of Aon Hewitt |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| John Burns | Option | 750 | 5.34 | — |
| Dragan Cicic | Option | 1,016 | 5.34 | — |
| Angelos Stergiou | Option | 3,438 | 5.34 | — |
| Dragan Cicic | RSU | 4,000 | — | 15,080 |
| John Burns | RSU | 5,000 | — | 18,850 |
| Angelos Stergiou | RSU | 14,500 | — | 54,665 |
| John Burns | RSU | 15,000 | — | 56,550 |
| Dragan Cicic | Option | 16,042 | 3.34 | — |
| John Burns | Option | 21,875 | 3.34 | — |
| Dragan Cicic | RSU | 22,500 | — | 84,825 |
| John Burns | RSU | 23,500 | — | 88,595 |
| Dragan Cicic | RSU | 25,000 | — | 94,250 |
| Dragan Cicic | Option | 33,854 | 0.52 | — |
| John Burns | Option | 39,063 | 0.52 | — |
| Angelos Stergiou | Option | 63,438 | 3.34 | — |
| Angelos Stergiou | RSU | 79,500 | — | 299,715 |
| Dragan Cicic | RSU | 84,750 | — | 319,508 |
| John Burns | RSU | 84,750 | — | 319,508 |
| Angelos Stergiou | RSU | 95,000 | — | 358,150 |
| Angelos Stergiou | Option | 124,219 | 0.52 | — |
| Dragan Cicic | Option | 169,500 | 0.95 | — |
| John Burns | Option | 169,500 | 0.95 | — |
| Angelos Stergiou | RSU | 192,750 | — | 726,668 |
| Angelos Stergiou | Option | 385,750 | 0.95 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| John VarianIndependent · Board Chair · Audit · Compensation · Science | $94,000 | $11,906 | $15,011 | — | — | $120,917 |
| David A. ScheinbergIndependent · Compensation · Science (Chair) | 66,000 | 11,906 | 15,011 | — | — | 92,917 |
| Robert L. Van NostrandIndependent · Audit · Nominating and Corporate Governance | 66,000 | 11,906 | 15,011 | — | — | 92,917 |
| Jane WasmanIndependent · Audit · Nominating and Corporate Governance (Chair) | 66,000 | 11,906 | 15,011 | — | — | 92,917 |
| Katherine Bach KalinIndependent · Compensation (Chair) · Nominating and Corporate Governance | 66,000 | 11,906 | 15,011 | — | — | 92,917 |
| Angelos M. StergiouEmployee director · Science | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 18,000 / 18,000 / 18,000 |
| Stock ownership guideline | Retail stockholders and Glass Lewis, however, requested more details on our stock ownership guidelines. As a result of this feedback, the Company has provided a summary of the stock ownership guidelines in this Proxy Statement |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $358,000 |
| Equity awards (grant-date value) | $59,530 |
| All other compensation | $0 |
| Total cost of the board | $417,530 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Sellas Life Sciences as a peer
Companies that benchmark against SLS
No companies currently name SLS as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Corvus Pharmaceuticals, Inc. | 2025 | Richard Miller | $36,566 | $0 | $6,989,000 | $0 | $7,031,566 |
| 2 | Compass Therapeutics | 2025 | Thomas Schuetz | 630,000 | 0 | 4,065,000 | 0 | 5,097,150 |
| 3 | Verastem, Inc. | 2025 | Daniel Paterson | 674,000 | 1,161,661 | 0 | 489,324 | 2,349,975 |
| 4 | Elevation Oncology, Inc. | 2024 | Joseph Ferra | 620,833 | 277,000 | 1,117,793 | 294,896 | 2,326,372 |
| 5 | Sellas Life Sciences Group | 2025 | Angelos Stergiou | 676,000 | 477,107 | 327,695 | 390,390 | 1,877,810 |
| 6 | Actinium Pharmaceuticals, Inc. | 2025 | Sandesh Seth | 762,320 | 0 | 0 | 0 | 1,187,320 |
| 7 | Cue Biopharma, Inc. | 2025 | Usman Azam | 143,077 | 0 | 1,042,313 | 0 | 1,185,639 |
| 8 | Syros Pharmaceuticals | 2023 | Conley Chee | 479,092 | 369,460 | 0 | 192,455 | 1,041,697 |
| 9 | PDS Biotechnology Corporation | 2025 | Frank Bedu-Addo | 615,322 | 0 | 193,500 | 0 | 828,307 |
| 10 | BeyondSpring Inc. | 2025 | Lan Huang | 452,920 | 0 | 37,522 | 201,323 | 702,182 |
| — | Cellectar Biosciences, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Checkpoint Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Equillium, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Immunic, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Leap Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Cidara Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Sellas Life Sciences Group | not disclosed | not disclosed | not disclosed | Radford, a division of Aon Hewitt |
| Actinium Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | StreeterWyatt Analytics LLC |
| BeyondSpring Inc. | not disclosed | Option 100 | not disclosed | not disclosed |
| Cellectar Biosciences, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Checkpoint Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Cidara Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Compass Therapeutics | not disclosed | not disclosed | not disclosed | Alpine Rewards |
| Corvus Pharmaceuticals, Inc. | not disclosed | Option 100 | not disclosed | not disclosed |
| Cue Biopharma, Inc. | not disclosed | Option 100 | not disclosed | Radford, an AON Hewitt company |
| Elevation Oncology, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards |
| Equillium, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Immunic, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Leap Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| PDS Biotechnology Corporation | not disclosed | not disclosed | not disclosed | not disclosed |
| Syros Pharmaceuticals | not disclosed | not disclosed | not disclosed | Compensia Inc. |
| Verastem, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-16 | 52,930,792 | 15,906,732 | 2,196,654 | 76.89% | Passed |
| 2025 | 2025-06-17 | 29,589,249 | 12,767,791 | 1,128,179 | 69.86% | Passed |
| 2024 | 2024-06-20 | 5,992,510 | 4,808,398 | 554,175 | 55.48% | Passed |
| 2023 | 2023-06-20 | 4,772,547 | 3,079,811 | 135,401 | 60.78% | Passed |
| 2022 | 2022-06-08 | 4,224,292 | 1,575,977 | 77,834 | 72.83% | Passed |
| 2021 | 2021-06-08 | 2,383,795 | 849,429 | 200,418 | 73.73% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-16 | 76.89%a |
| 2025 | 2025-06-17 | 69.86%b |
| 2024 | 2024-06-20 | 55.48%c |
a. Approved under the standard stated in the filing — “Although there is no "required vote" that would constitute approval for this Proposal 4, non-binding advisory approval of this Proposal 4 requires that the proposal receive "FOR" votes from the holders of a majority of the shares voting online or represented by proxy and entitled to vote on the matter at the 2026 Annual Meeting that cast votes with respect to this Proposal 4. || Abstentions: Abstentions and broker non-votes will count towards a quorum but will have no effect on the outcome of this Proposal 4.”.
b. Approved under the standard stated in the filing — “Although there is no "required vote" that would constitute approval for this Proposal 4, non-binding advisory approval of this Proposal 4 requires that the proposal receive "FOR" votes from the holders of a majority of the shares voting online or represented by proxy and entitled to vote on the matter at the 2025 Annual Meeting that cast votes with respect to this Proposal 4. || Abstentions: Abstentions and broker non-votes will count towards a quorum but will have no effect on the outcome of this Proposal 4.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will count towards a quorum but will have no effect on the outcome of this Proposal 3.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (24 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Angelos Stergiou. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 23. As printed: 1,877,810. View filing ↗
- Section 01, Dragan Cicic. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table”. As printed: 991,795. View filing ↗
- Section 01, John Burns. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table”. As printed: 959,653. View filing ↗
- Section 08, John Varian. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 120,917. View filing ↗
- Section 08, David A. Scheinberg. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 92,917. View filing ↗
- Section 08, Robert L. Van Nostrand. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 92,917. View filing ↗
- Section 08, Jane Wasman. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 92,917. View filing ↗
- Section 08, Katherine Bach Kalin. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 92,917. View filing ↗
- Section 08, Angelos M. Stergiou. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-18. Item 5.07 · say-on-pay result. As reported: 76.89% (votes for as printed: 52,930,792). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-18. Item 5.07 · say-on-pay result. As reported: 69.86% (votes for as printed: 29,589,249). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-21. Item 5.07 · say-on-pay result. As reported: 55.48% (votes for as printed: 5,992,510). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 358,000 + equity 59,530 + all other 0 = 417,530, summed across the director compensation table rows.
- Corvus Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Corvus Pharmaceuticals, Inc.'s own proxy. As printed: 7,031,566. View filing ↗
- Compass Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Compass Therapeutics's own proxy. As printed: 5,097,150. View filing ↗
- Verastem, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Verastem, Inc.'s own proxy. As printed: 2,349,975. View filing ↗
- Elevation Oncology, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Elevation Oncology, Inc.'s own proxy. As printed: 2,326,372. View filing ↗
- Sellas Life Sciences Group (subject), Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Sellas Life Sciences Group's own proxy. As printed: 1,877,810. View filing ↗
- Actinium Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-16. CEO total compensation as printed in Actinium Pharmaceuticals, Inc.'s own proxy. As printed: 1,187,320. View filing ↗
- Cue Biopharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Cue Biopharma, Inc.'s own proxy. As printed: 1,185,639. View filing ↗
- Syros Pharmaceuticals, Section 10b CEO total. 10-K, filed 2024-04-23. CEO total compensation as printed in Syros Pharmaceuticals's own proxy. As printed: 1,041,697. View filing ↗
- PDS Biotechnology Corporation, Section 10b CEO total. DEF 14A, filed 2026-06-26. CEO total compensation as printed in PDS Biotechnology Corporation's own proxy. As printed: 828,307. View filing ↗
- BeyondSpring Inc., Section 10b CEO total. 10-K, filed 2026-03-25. CEO total compensation as printed in BeyondSpring Inc.'s own proxy. As printed: 702,182. View filing ↗